Our site may be slower due to heavy traffic from automated "bots" and AI crawlers. We're working to fix this.

Nathan Curry

Title(s)Sr. CRC, HDF Comprehensive Cancer Ctr
SchoolSchool of Medicine
Address550 16th Street, #6871
San Francisco CA 94158
PronounsHe/Him/His
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Featured Publications

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. EV-PRIME: Phase Ib/II study of enfortumab vedotin and pembrolizumab combined with radiotherapy as a bladder-sparing trimodality therapy in muscle invasive bladder cancer. Vadim S. Koshkin, Steven N. Seyedin, Li Zhang, Nathan Curry, Kelly N. Fitzgerald, Nonna Shakhnazaryan, Beaux Mitchell, Vipul Kumar, Ivan de Kouchkovsky, Julian C. Hong, Maxwell Meng, Xiaolin Zhu, Rahul R. Aggarwal, Chien-Kuang C. Ding, David Y. Oh, Carissa E. Chu, Terence W. Friedlander, Jonathan Chou, Anthony C. Wong, Sima P. Porten. View Publication.
    2. A phase 1b dose escalation study of FOR46, a novel antibody-drug conjugate targeting a tumor-specific epitope of CD46, in combination with enzalutamide (Enza) in patients with metastatic castration resistant prostate cancer (mCRPC). Nonna Shakhnazaryan, Nathan Curry, Medini Rastogi, Daniel Avins, Shrina Pandey, Ivan de Kouchkovsky, Daniel Kwon, Arpita Desai, Kelly N. Fitzgerald, Rohit Bose, Jonathan Chou, Terence W. Friedlander, Vadim S Koshkin, Lawrence Fong, Maya Aslam, Khadija Siddiqua, Eric J. Small, Bin Liu, Robert R. Flavell, Rahul Raj Aggarwal. View Publication.
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-21-g9d46e6c4 on PROFILES-PWEB04.

    Copyright © The Regents of the University of California.